Inovio Pharmaceuticals, Inc. (NASDAQ: INO) insider Laurent Humeau sold 10,318 shares of the company in a trade that took place on Wednesday, June 9. The stock was sold for an average price of $ 9.07, for a total value of $ 93,584.26. The transaction was disclosed in a legal file with the SEC, which is available at the SEC website.
INO traded down $ 0.05 in Friday’s session, reaching $ 9.10. 3,754,922 company shares traded for an average volume of 12,260,720. The company’s 50-day moving average is $ 7.74. The company has a debt to equity ratio of 0.02, a current ratio of 14.17 and a rapid ratio of 14.17. Inovio Pharmaceuticals, Inc. has a 12-month low of $ 5.81 and a 12-month high of $ 33.79. The company has a market cap of $ 1.91 billion, a PE ratio of -8.05 and a beta of 0.66.
Inovio Pharmaceuticals (NASDAQ: INO) last released its quarterly results on Monday, May 10. The biopharmaceutical company reported ($ 0.27) earnings per share for the quarter, missing the consensus estimate of ($ 0.18) of ($ 0.09). The company posted revenue of $ 0.40 million for the quarter, compared to a consensus estimate of $ 1.06 million. Inovio Pharmaceuticals had a negative net margin of 2,916.64% and a negative return on equity of 39.16%. Inovio Pharmaceuticals revenue for the quarter was down 69.2% year-on-year. As a group, sell-side analysts expect Inovio Pharmaceuticals, Inc. to post earnings per share of -1.07 for the current year.
Several analysts have recently looked at INO shares. Zacks investment research downgraded Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 13. Bank of America began covering Inovio Pharmaceuticals in a research note on Tuesday, March 23. They issued a “neutral” rating and a target price of $ 13.00 on the stock. Oppenheimer reaffirmed a “buy” note on Inovio Pharmaceuticals shares in a research note on Friday, April 16. Piper Sandler reduced her price target on Inovio Pharmaceuticals from $ 7.00 to $ 6.00 and set the stock “neutral” rating in a research note on Monday, May 10. Finally, HC Wainwright reaffirmed a “conservation” note on Inovio Pharmaceuticals shares in a research note on Friday April 16. Two research analysts rated the stock with a sell rating, five assigned a conservation rating, and three issued a buy rating for the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $ 15.63.
Several hedge funds and other institutional investors have recently increased or reduced their stakes in the company. Banque Cantonale Vaudoise increased its stake in Inovio Pharmaceuticals shares by 6.5% in the 4th quarter. Banque Cantonale Vaudoise now owns 15,722 shares of the biopharmaceutical company valued at $ 139,000 after purchasing 955 additional shares during the period. LPL Financial LLC increased its stake in Inovio Pharmaceuticals shares by 2.2% during the 4th quarter. LPL Financial LLC now owns 45,968 shares of the biopharmaceutical company valued at $ 407,000 after purchasing an additional 976 shares during the period. Orion Portfolio Solutions LLC increased its stake in Inovio Pharmaceuticals shares by 11.7% in the 4th quarter. Orion Portfolio Solutions LLC now owns 11,383 shares of the biopharmaceutical company valued at $ 101,000 after purchasing an additional 1,188 shares during the period. Advisory Services Network LLC increased its stake in Inovio Pharmaceuticals shares by 42.4% during the 4th quarter. Advisory Services Network LLC now owns 4,200 shares of the biopharmaceutical company valued at $ 37,000 after purchasing an additional 1,250 shares during the period. Finally, Mayflower Financial Advisors LLC increased its stake in Inovio Pharmaceuticals shares by 4.6% during the first quarter. Mayflower Financial Advisors LLC now owns 30,402 shares of the biopharmaceutical company valued at $ 282,000 after purchasing an additional 1,326 shares during the period. 35.18% of the shares are currently held by hedge funds and other institutional investors.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc, a biotechnology company, is focused on the discovery, development and commercialization of DNA-based drugs to treat and protect people against diseases associated with human papillomavirus (HPV), cancer and infectious diseases. Its DNA-based drug platform uses precisely engineered SynCon optimized plasmids that have the ability to help break the immune system’s tolerance to cancerous or infected cells and to facilitate protection against cross-strains against variants. of unpaired and paired pathogens.
Feature Article: Fundamental Analysis – How It Helps Investors
This instant news alert was powered by narrative science technology and MarketBeat financial data to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured article: What is the Nikkei 225 Index?
7 sports betting stocks that will shine beyond the madness of March
One of the many consequences of the new coronavirus has been the cessation of live sports. For athletes, one of the most missed events was the NCAA basketball tournament affectionately known as March Madness.
But in addition to missing out on the entertainment that sport offers, cities and states have realized, if they hadn’t already, that sport is an economic necessity.
Live sports may also be a key to their post-pandemic future. But it goes beyond hotels and restaurants.
Sports betting has become big business. Currently, 25 states and the District of Columbia have legalized sports betting either by law or by ballot. This list is likely to grow longer. Many states are facing budget deficits and want to legalize sports betting for the revenue they could earn from it.
And it’s not just about allowing players to place bets through a bookmaker in a casino. The real driver of this is mobile sports betting. According to the American Gaming Association, more than 47 million people are expected to place bets during the NCAA basketball tournament, with about a third of those bets (17.8 million) being placed online.
To help you take advantage of this ever-emerging trend, we’ve put together this special presentation. Here, we’ll highlight seven sports betting stocks that are expected to generate significant income during March Madness and beyond.
Check out the “7 Sports Betting Actions That Will Shine Beyond The March Madness.”